- Our Company
- News & Events
- Contact Us
Hear what Prof. David Gandara, MD, a world-renowned oncologist, has to say about Guardant360® CDx becoming the first liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers. This one-minute video clip is captured from a recently conducted webinar earlier this month.
Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at firstname.lastname@example.org or contact us on WhatsApp: +65 8940 0360.
Guardant360®. Test. Take Action.
View full press release at this link: https://lnkd.in/gwAmpCD